免疫系统
封锁
免疫学
医学
CTLA-4号机组
炎症
结肠炎
免疫检查点
免疫疗法
T细胞
内科学
受体
作者
Yifan Zhou,Yusra B. Medik,Bhakti Patel,Daniel B. Zamler,Sijie Chen,Thomas Chapman,Sarah M. Schneider,Elizabeth M. Park,Rachel Lauren Babcock,Taylor T. Chrisikos,Laura M. Kahn,Allison M. Dyevoich,Josue Estiven Pineda,Matthew C. Wong,Aditya K. Mishra,Samuel H. Cass,Alexandria P. Cogdill,Daniel Hartman Johnson,Sarah B. Johnson,Khalida Wani
摘要
Immune checkpoint blockade (ICB) has revolutionized cancer treatment, yet quality of life and continuation of therapy can be constrained by immune-related adverse events (irAEs). Limited understanding of irAE mechanisms hampers development of approaches to mitigate their damage. To address this, we examined whether mice gained sensitivity to anti-CTLA-4 (αCTLA-4)-mediated toxicity upon disruption of gut homeostatic immunity. We found αCTLA-4 drove increased inflammation and colonic tissue damage in mice with genetic predisposition to intestinal inflammation, acute gastrointestinal infection, transplantation with a dysbiotic fecal microbiome, or dextran sodium sulfate administration. We identified an immune signature of αCTLA-4-mediated irAEs, including colonic neutrophil accumulation and systemic interleukin-6 (IL-6) release. IL-6 blockade combined with antibiotic treatment reduced intestinal damage and improved αCTLA-4 therapeutic efficacy in inflammation-prone mice. Intestinal immune signatures were validated in biopsies from patients with ICB colitis. Our work provides new preclinical models of αCTLA-4 intestinal irAEs, mechanistic insights into irAE development, and potential approaches to enhance ICB efficacy while mitigating irAEs.
科研通智能强力驱动
Strongly Powered by AbleSci AI